+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bioidentical Hormones Market - Global Forecast to 2030- Product Image
Bioidentical Hormones Market - Global Forecast to 2030- Product Image
Sale

Bioidentical Hormones Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011384
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bioidentical Hormones Market grew from USD 616.46 million in 2024 to USD 773.91 million in 2025. It is expected to continue growing at a CAGR of 25.09%, reaching USD 2.36 billion by 2030.

The bioidentical hormones sector sits at the intersection of personalized medicine and patient-centered wellness, evolving rapidly under the pressures of demographic change and technological innovation. Aging populations across developed economies drive demand for therapies that address menopause, andropause, thyroid dysfunction and other endocrine imbalances with greater safety and efficacy than traditional hormone replacement. Concurrently, heightened patient awareness about treatment options and a growing preference for “natural” formulations have elevated bioidentical therapies into mainstream clinical practice.

Regulatory bodies in North America and Europe have begun to clarify pathways for approval and quality standards, reducing barriers to market entry and encouraging new product launches. At the same time, advances in compounding techniques and formulation science have expanded the portfolio of delivery mechanisms-from transdermal patches and topical creams to implantable devices and injectable solutions. Supported by a robust pipeline of clinical studies and an expanding roster of specialty providers, the market is poised for sustained growth.

As stakeholders navigate this dynamic environment, they face complex challenges related to supply chain resilience, pricing pressure and regulatory compliance. In this context, a deep understanding of market drivers, segmentation patterns and competitive dynamics becomes essential for organizations aiming to capture value and drive innovation.

Transformative Shifts Redefining the Hormone Therapy Sector

The hormone therapy sector is undergoing transformative shifts that are reshaping product development, distribution and patient engagement. First, the rise of digital health platforms and telemedicine services has enabled remote prescribing, virtual monitoring and data-driven personalization of dosing regimens. Clinicians now leverage wearable sensors and mobile apps to track symptom relief in real time, adjusting hormone levels with unprecedented precision.

Second, artificial intelligence and advanced analytics are accelerating biomarker discovery, enabling the identification of novel receptor targets and optimizing formulation stability. These tools also streamline regulatory submissions by predicting clinical outcomes and ensuring batch‐to‐batch consistency.

Third, sustainability trends are driving formulators to explore plant-derived and synthetic sources that reduce reliance on animal-based precursors. This shift aligns with consumer demand for ethical, eco-friendly products and anticipates tighter environmental regulations.

Fourth, distribution channels are fragmenting as online pharmacies and direct-to-consumer models complement traditional hospital, retail and drugstore outlets. Manufacturers are forging strategic alliances with compounding pharmacies and telehealth providers to deliver end-to-end patient solutions, integrating hormonal therapies with nutritional guidance and lifestyle interventions.

Collectively, these shifts herald a more agile, patient-centric industry that balances scientific rigor with market responsiveness.

Assessing the Cumulative Impact of United States Tariffs 2025 on Bioidentical Hormones

In 2025, new tariffs imposed by the United States on select active pharmaceutical ingredients and hormone precursors are reshaping cost structures across the bioidentical hormone supply chain. Manufacturers importing estradiol, progesterone and related intermediates face higher input costs, which compounders and branded producers may need to pass along to healthcare providers and end users. This cost pressure challenges traditional pricing models and compels firms to explore alternative sourcing strategies.

To mitigate tariff-related disruptions, some companies have accelerated nearshoring efforts by partnering with domestic API producers and commissioning local synthesis facilities. Vertical integration has gained traction as a hedge against future trade policy volatility, allowing firms to secure quality-controlled supply and maintain margin stability.

Simultaneously, the tariff landscape is prompting a pivot toward synthetic and plant-based raw materials that evade specific import duties. While this transition entails upfront R&D investment, it also opens opportunities for differentiated positioning-particularly in markets where consumers prioritize “green” manufacturing.

Although short-term fluctuations in raw material costs may introduce volatility, proactive supply chain optimization and strategic partnerships can preserve profitability. Looking ahead, tariff-driven supply chain realignment is set to foster greater domestic capacity, spur innovation in precursor chemistry and bolster long-term industry resilience.

Key Segmentation Insights Driving Targeted Growth Strategies

A nuanced view of the market emerges when dissecting product type, formulation type, end user, application, route of administration, source, endocrine disorder addressed, patient age group, distribution channel and therapeutic area. Combination therapies continue to gain traction by addressing multiple hormonal imbalances in a single regimen, while estradiol-based and estrogen-based hormones retain prominence for menopause management. Progesterone and testosterone therapies respond to rising awareness of hypoactive sexual desire and andropause, respectively.

In terms of formulation, capsules and tablets dominate convenience-oriented segments, whereas creams, patches and injections cater to patients seeking steady hormone release profiles. Men constitute a smaller but growing share of prescriptions, particularly for androgen deficiency, while women-across pre-menopausal and post-menopausal stages-remain the core demographic.

Clinical applications cluster around menopause management, thyroid dysfunction, adrenal functioning issues and infertility, each demanding tailored dosing and monitoring protocols. Implantable devices and transdermal systems lead in adherence rates, although oral and topical routes command the largest patient base.

Plant-based sources attract health-conscious consumers, synthetic precursors satisfy rigorous purity standards and animal-based extracts appeal to traditionalists. Endocrine disorders such as PCOS, hypogonadism, hypothyroidism and andropause drive specific therapy design, and patient age groups from pre-teens to the elderly require distinct safety and efficacy profiles. Distribution channels span drug stores, hospital and retail pharmacies plus burgeoning online outlets. Finally, therapeutic applications in chronic diseases, gynecology, oncology and orthopedics underscore the sector’s cross-disciplinary impact.

Regional Dynamics Shaping Bioidentical Hormone Market Performance

Regional dynamics underscore the heterogeneity of demand, regulatory frameworks and competitive landscapes. In the Americas, robust healthcare infrastructure and favorable reimbursement policies support rapid adoption of advanced bioidentical therapies. The United States leads in R&D investment and private pay models, while Canada’s provincial formularies encourage evidence-based prescribing.

Within Europe, Middle East & Africa, the market experiences a patchwork of regulatory regimes: stringent approval pathways in Western Europe contrast with emerging interest in hormone therapies across the Gulf Cooperation Council and North Africa. Economic pressures in parts of EMEA drive cost-effective compounding solutions, creating opportunities for niche players.

Asia-Pacific presents the highest growth potential, fueled by rising disposable incomes, aging populations and growing awareness of hormone balance in China, Japan and India. Telehealth expansion and liberalized pharmacy ownership rules in Australia and Southeast Asia streamline patient access. However, diverse cultural attitudes toward bioidentical hormones and varied reimbursement structures require tailored market entry strategies.

Profiling Leading Companies Innovating in Bioidentical Hormones

A diverse competitive landscape combines multinational pharmaceutical giants, specialized compounding pharmacies and integrated wellness centers. AbbVie Inc. and Pfizer Inc. leverage extensive clinical trial portfolios and global distribution networks to maintain leadership in hormone therapies. Bayers AG and Novartis AG complement their mainstream offerings with targeted initiatives in formulation innovation.

Biote Medical, LLC and Defy Medical, LLC pioneered direct-to-patient models, offering telehealth-enabled hormone optimization programs. NextGenRx Compounding Pharmacy and Pavilion Compounding Pharmacy, LLC distinguish themselves through precision compounding services tailored to individual biomarker profiles. Full Life Wellness Center and Optimal Health and Wellness integrate hormonal therapies with functional medicine, promoting holistic care.

Novan Pharmaceuticals, Inc. and Nueva Aesthetics explore novel topical applications, while Merck KGaA and Novo Nordisk A/S emphasize plant-based and synthetic source development. Hisamitsu Group applies transdermal patch technology originally designed for pain management to hormone delivery. Pellecome, LLC and Schwietermans Pharmacy excel in specialty formulations, and The Biostation and TherapeuticsMD, Inc. collaborate on clinical education and patient engagement.

Actionable Recommendations for Industry Leaders to Capitalize on Trends

Industry leaders should prioritize five key actions to capitalize on emerging opportunities. First, invest in advanced data analytics and AI to refine patient stratification and optimize dosage protocols, reducing trial-and-error adjustments. Second, expand digital health and telemedicine partnerships to deliver seamless care pathways, from prescription through ongoing monitoring. Third, diversify raw-material sourcing by forging alliances with plant-based extractors and synthetic API manufacturers to mitigate supply chain risk and meet sustainability benchmarks.

Fourth, enhance regulatory engagement by proactively collaborating with authorities on quality standards and post-market surveillance initiatives, accelerating approval timelines and building stakeholder trust. Fifth, adopt a modular portfolio strategy that spans implantable, transdermal, oral and topical formats, enabling rapid response to shifting patient preferences and therapeutic needs. Sixth, consider selective vertical integration or strategic joint ventures to bolster domestic manufacturing capacity in response to tariff-induced disruptions.

By embedding these actions into corporate roadmaps, organizations can strengthen competitive advantage, drive margin expansion and foster long-term resilience.

Conclusion: Strategic Imperatives for Future Market Success

The bioidentical hormones market stands at a strategic inflection point, where demographic imperatives, technological breakthroughs and evolving trade policies converge. Success will hinge on an organization’s ability to integrate patient-centric digital solutions with robust supply chain architectures and diversified formulation capabilities. Firms that align R&D investment with sustainability goals and regulatory foresight will capture disproportionate market share, while those that neglect emerging distribution channels risk ceding ground to agile entrants.

A disciplined focus on segmentation-across product, formulation, end user, application and other vectors-enables precise value propositions and targeted commercialization. Concurrently, regional expansion must account for regulatory complexity and cultural nuance, leveraging localized partnerships to expedite market access. By synthesizing these strategic imperatives, industry players can unlock new growth trajectories and deliver superior therapeutic outcomes.

Market Segmentation & Coverage

This research report categorizes the Bioidentical Hormones Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Combination Therapies
  • Estradiol-Based Hormones
  • Estrogen-Based Hormones
  • Progesterone-Based Hormones
  • Testosterone-Based Hormones
  • Capsules
  • Creams
  • Injections
  • Patches
  • Tablets
  • Men
  • Women
    • Post-Menopausal
    • Pre-Menopausal
  • Adrenal Functioning Issues
  • Infertility
  • Menopause Management
  • Thyroid Dysfunction
  • Implants
  • Oral
  • Topical
  • Transdermal
  • Animal-Based
  • Plant-Based
  • Synthetic
  • Andropause
  • Hypogonadism
  • Hypothyroidism
  • PCOS
  • Elderly
  • Middle Age
  • Pre-Teen
  • Teenagers
  • Young Adults
  • Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Chronic Diseases
  • Gynecology
  • Oncology
  • Orthopedics

This research report categorizes the Bioidentical Hormones Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Bioidentical Hormones Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Bayers AG
  • Biote Medical, LLC
  • Defy Medical, LLC
  • Full Life Wellness Center
  • Merck KGaA
  • NextGenRx Compounding Pharmacy
  • Novartis AG
  • Noven Pharmaceuticals, Inc. Hisamitsu Group
  • Novo Nordisk A/S
  • Nueva Aesthetics
  • Optimal Health and Wellness
  • Pavilion Compounding Pharmacy, LLC
  • Pellecome, LLC
  • Pfizer Inc.
  • Schwietermans Pharmacy
  • The Biostation
  • TherapeuticsMD, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bioidentical Hormones Market, by Product Type
8.1. Introduction
8.2. Combination Therapies
8.3. Estradiol-Based Hormones
8.4. Estrogen-Based Hormones
8.5. Progesterone-Based Hormones
8.6. Testosterone-Based Hormones
9. Bioidentical Hormones Market, by Formulation Type
9.1. Introduction
9.2. Capsules
9.3. Creams
9.4. Injections
9.5. Patches
9.6. Tablets
10. Bioidentical Hormones Market, by End User
10.1. Introduction
10.2. Men
10.3. Women
10.3.1. Post-Menopausal
10.3.2. Pre-Menopausal
11. Bioidentical Hormones Market, by Application
11.1. Introduction
11.2. Adrenal Functioning Issues
11.3. Infertility
11.4. Menopause Management
11.5. Thyroid Dysfunction
12. Bioidentical Hormones Market, by Route Of Administration
12.1. Introduction
12.2. Implants
12.3. Oral
12.4. Topical
12.5. Transdermal
13. Bioidentical Hormones Market, by Source
13.1. Introduction
13.2. Animal-Based
13.3. Plant-Based
13.4. Synthetic
14. Bioidentical Hormones Market, by Endocrine Disorder Addressed
14.1. Introduction
14.2. Andropause
14.3. Hypogonadism
14.4. Hypothyroidism
14.5. PCOS
15. Bioidentical Hormones Market, by Patient Age Group
15.1. Introduction
15.2. Elderly
15.3. Middle Age
15.4. Pre-Teen
15.5. Teenagers
15.6. Young Adults
16. Bioidentical Hormones Market, by Distribution Channel
16.1. Introduction
16.2. Drug Stores
16.3. Hospital Pharmacies
16.4. Online Pharmacies
16.5. Retail Pharmacies
17. Bioidentical Hormones Market, by Therapeutic Area
17.1. Introduction
17.2. Chronic Diseases
17.3. Gynecology
17.4. Oncology
17.5. Orthopedics
18. Americas Bioidentical Hormones Market
18.1. Introduction
18.2. Argentina
18.3. Brazil
18.4. Canada
18.5. Mexico
18.6. United States
19. Asia-Pacific Bioidentical Hormones Market
19.1. Introduction
19.2. Australia
19.3. China
19.4. India
19.5. Indonesia
19.6. Japan
19.7. Malaysia
19.8. Philippines
19.9. Singapore
19.10. South Korea
19.11. Taiwan
19.12. Thailand
19.13. Vietnam
20. Europe, Middle East & Africa Bioidentical Hormones Market
20.1. Introduction
20.2. Denmark
20.3. Egypt
20.4. Finland
20.5. France
20.6. Germany
20.7. Israel
20.8. Italy
20.9. Netherlands
20.10. Nigeria
20.11. Norway
20.12. Poland
20.13. Qatar
20.14. Russia
20.15. Saudi Arabia
20.16. South Africa
20.17. Spain
20.18. Sweden
20.19. Switzerland
20.20. Turkey
20.21. United Arab Emirates
20.22. United Kingdom
21. Competitive Landscape
21.1. Market Share Analysis, 2024
21.2. FPNV Positioning Matrix, 2024
21.3. Competitive Analysis
21.3.1. AbbVie Inc.
21.3.2. Bayers AG
21.3.3. Biote Medical, LLC
21.3.4. Defy Medical, LLC
21.3.5. Full Life Wellness Center
21.3.6. Merck KGaA
21.3.7. NextGenRx Compounding Pharmacy
21.3.8. Novartis AG
21.3.9. Noven Pharmaceuticals, Inc. Hisamitsu Group
21.3.10. Novo Nordisk A/S
21.3.11. Nueva Aesthetics
21.3.12. Optimal Health and Wellness
21.3.13. Pavilion Compounding Pharmacy, LLC
21.3.14. Pellecome, LLC
21.3.15. Pfizer Inc.
21.3.16. Schwietermans Pharmacy
21.3.17. The Biostation
21.3.18. TherapeuticsMD, Inc.
22. ResearchAI
23. ResearchStatistics
24. ResearchContacts
25. ResearchArticles
26. Appendix
List of Figures
FIGURE 1. BIOIDENTICAL HORMONES MARKET MULTI-CURRENCY
FIGURE 2. BIOIDENTICAL HORMONES MARKET MULTI-LANGUAGE
FIGURE 3. BIOIDENTICAL HORMONES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 26. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 30. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. BIOIDENTICAL HORMONES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 36. BIOIDENTICAL HORMONES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BIOIDENTICAL HORMONES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ESTRADIOL-BASED HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ESTROGEN-BASED HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PROGESTERONE-BASED HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TESTOSTERONE-BASED HORMONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY CREAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY MEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY POST-MENOPAUSAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRE-MENOPAUSAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ADRENAL FUNCTIONING ISSUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY INFERTILITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY MENOPAUSE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY THYROID DYSFUNCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ANIMAL-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PLANT-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ANDROPAUSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HYPOGONADISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PCOS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ELDERLY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY MIDDLE AGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY PRE-TEEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY TEENAGERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY CHRONIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY GYNECOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BIOIDENTICAL HORMONES MARKET SIZE, BY ORTHOPEDICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 93. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 95. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 97. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 100. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 101. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 102. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. CANADA BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 104. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 108. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 112. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 113. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. MEXICO BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 126. UNITED STATES BIOIDENTICAL HORMONES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 150. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 152. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 154. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 157. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 158. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. CHINA BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 161. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 163. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 165. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 166. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 168. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 169. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 170. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. INDIA BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 183. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 185. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 187. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 188. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 190. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 191. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. JAPAN BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 194. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 205. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 207. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 216. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 227. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 229. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 238. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 239. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 240. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 242. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 243. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 245. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 246. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 247. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. TAIWAN BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 249. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 250. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 251. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 253. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 256. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 257. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. THAILAND BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 260. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 262. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 264. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 267. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 268. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA BIOIDENTICAL HORMONES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 283. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 285. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 287. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 290. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 291. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 292. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. DENMARK BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 294. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 295. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 296. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 298. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 299. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 300. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 301. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 302. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 303. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 304. EGYPT BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 305. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 306. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 307. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 309. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 310. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 311. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 312. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 313. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 314. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 315. FINLAND BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 316. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 317. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 318. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 320. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 321. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 322. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 323. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY ENDOCRINE DISORDER ADDRESSED, 2018-2030 (USD MILLION)
TABLE 324. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 325. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 326. FRANCE BIOIDENTICAL HORMONES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
TABLE 327. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 329. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 330. GERMANY BIOIDENTICAL HORMONES MARKET SIZE, BY WOMEN, 2018-2030 (USD MILLION)
TABLE 331. GERMA

Companies Mentioned

  • AbbVie Inc.
  • Bayers AG
  • Biote Medical, LLC
  • Defy Medical, LLC
  • Full Life Wellness Center
  • Merck KGaA
  • NextGenRx Compounding Pharmacy
  • Novartis AG
  • Noven Pharmaceuticals, Inc. Hisamitsu Group
  • Novo Nordisk A/S
  • Nueva Aesthetics
  • Optimal Health and Wellness
  • Pavilion Compounding Pharmacy, LLC
  • Pellecome, LLC
  • Pfizer Inc.
  • Schwietermans Pharmacy
  • The Biostation
  • TherapeuticsMD, Inc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Bioidentical Hormones Market Report 2025 - Product Image

Bioidentical Hormones Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Synthetic Hormones Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Synthetic Hormones Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Synthetic Hormones Market - Global Forecast to 2030 - Product Image

Synthetic Hormones Market - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global
From
Human Growth Hormone Market by Route of Administration, Type, Distribution, Application - Global Forecast 2025-2030 - Product Image

Human Growth Hormone Market by Route of Administration, Type, Distribution, Application - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Human Growth Hormone (HGH) - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Human Growth Hormone (HGH) - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From

About the Bioidentical Hormones Market

Bioidentical hormones are biotechnological products that are chemically identical to hormones naturally produced by the human body. They are used to treat a variety of medical conditions, including menopause, andropause, and hormone imbalances. Bioidentical hormones are typically derived from plant sources, such as yams and soybeans, and are then synthesized in a laboratory to create a product that is identical to the hormones produced by the body. Bioidentical hormones are becoming increasingly popular due to their ability to provide relief from symptoms associated with hormone imbalances without the side effects associated with traditional hormone replacement therapies. They are also seen as a more natural alternative to synthetic hormones. The bioidentical hormones market is growing rapidly, driven by increasing awareness of the benefits of bioidentical hormones and the availability of more affordable products. The market is expected to continue to grow in the coming years as more people become aware of the potential benefits of bioidentical hormones. Some companies in the bioidentical hormones market include BioTE Medical, BHRT Solutions, and Compounding Solutions. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.